Cytospire Therapeutics

Next generation immune cell engagers for cancer

London, United States · Founded 2023 · $182.0M raised

Headquarters
London
Employees
11–50
Founded
2023
Business Model
B2B
Total Funding
$182.0M
Last Round
$83.0M Venture RoundMay 2026
Rounds
2

About

Cytospire Therapeutics is a UK-based clinical-stage biotechnology company developing next-generation multispecific immune cell engagers for cancer treatment. Its lead programs are pan-gamma delta (γδ) T cell engagers designed to direct the innate and adaptive immune system against tumors, offering a safer and more tailored alternative to CD3-based engagers. The company was founded by leadership previously at Adaptate Biotherapeutics and GammaDelta Therapeutics, both acquired by Takeda Pharmaceuticals, and raised an oversubscribed £61 million ($83M) Series A in May 2026 led by 4BIO Capital.

Summary

Cytospire Therapeutics is a Biotech company based in London, United States, founded in 2023. It has raised $182.0M in total across 2 rounds, most recently a $83.0M Venture Round round in May 2026. Investors include 4BIO Capital, Servier Ventures and British Business Bank.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundMay 2026
$83.0M

Sign up to see all 2 rounds

Venture Round through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cytospire Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/cytospire-therapeutics"><img src="https://indexed.vc/api/badge/company/cytospire-therapeutics" alt="Cytospire Therapeutics on Indexed.vc" width="260" height="76" /></a>